Get Real Time Here
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News Summary
Acumen Pharmaceuticals Stock (NASDAQ: ABOS) stock price, news, charts, stock research, profile.
| Open4.220 | Close4.150 |
| Vol / Avg.229.963K / 1.113M | Mkt Cap245.941M |
| Day Range4.110 - 4.230 | 52 Wk Range3.520 - 11.310 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.360 | -0.280 | 0.0800 | ||||
| REV | 0 |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-09 | Credit Suisse | Judah Frommer | Reiterates | OutperformOutperform | Maintains | - | 13.00 |
| 2023-08-09 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-07-20 | B of A Securities | Geoff Meacham | Reinstates | Buy | Announces | - | 14.00 |
| 2023-07-17 | Cantor Fitzgerald | Pete Stavropoulos | Reiterates | OverweightOverweight | Maintains | - | 13.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ABOS | Acumen Pharmaceuticals | 1.92% | 245.9M |
| RENB | Renovaro Biosciences | 4.42% | 270.7M |
| IPHA | Innate Pharma | -4.17% | 203.7M |
| INZY | Inozyme Pharma | -0.59% | 259.3M |
| IMRX | Immuneering | -1.92% | 224.7M |
How do I buy Acumen Pharmaceuticals (ABOS) stock?
You can purchase shares of Acumen Pharmaceuticals (NASDAQ: ABOS) through any online brokerage.
Who are Acumen Pharmaceuticals's (ABOS) competitors?
Other companies in Acumen Pharmaceuticals’s space includes: Renovaro Biosciences (NASDAQ:RENB), Innate Pharma (NASDAQ:IPHA), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Fate Therapeutics (NASDAQ:FATE).
What is the target price for Acumen Pharmaceuticals (ABOS) stock?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by Credit Suisse on Wednesday, August 9, 2023. The analyst firm set a price target for 13.00 expecting ABOS to rise to within 12 months (a possible 205.88% upside). 11 analyst firms have reported ratings in the last year.
Current Stock Price for Acumen Pharmaceuticals (ABOS)?
The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $4.25 last updated September 29, 2023 at 12:45 PM UTC.
Does Acumen Pharmaceuticals (ABOS) pay a dividend?
There is no dividend information for Acumen Pharmaceuticals.
When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?
Acumen Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
Is Acumen Pharmaceuticals (ABOS) going to split?
There is no upcoming split for Acumen Pharmaceuticals.
What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?
Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.